United States (National)
Not enough data
Derrick Gingery's coverage primarily focuses on the healthcare and pharmaceutical industry in the United States, with a strong emphasis on government announcements, legal policy regulation, and press releases. He appears to be particularly interested in developments related to the US FDA, regulations impacting drug development, and medical research.
Given his focus on regulatory changes within the pharmaceutical industry at a national level, Derrick would likely respond well to pitches from experts familiar with US FDA procedures and policies or individuals directly impacted by these regulatory changes. Consider offering insights into how specific regulations or government announcements may affect drug development processes or medical research within the United States.
Since he covers topics related to pharmaceuticals and healthcare regulations extensively without an international focus mentioned explicitly, it is best to tailor pitches that are relevant specifically to U.S. regulatory matters rather than global issues.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Derrick Gingery
‘America First' elements are included in the commitment letter negotiated between the US FDA and the generics industry. ANDA fees could decrease, and new incentives, such as early inspections, would encourage US-based manufacturing.
By: Derrick Gingery
The GDUFA IV commitment letter will rename formal meetings and streamline its structure, as well as create a new goal date extension for complex regulatory issues.
By: Derrick Gingery
After the controversial remake of the Advisory Committee on Immunization Practices, which remains in legal limbo, HHS is looking for nominees for another vaccine panel and has expanded the pool of potential members.
By: Derrick Gingery
Newly finalized guidance states that follow-up questions from prior discussions may be appropriate for Type D meetings, but INTERACT meetings are not appropriate for sponsors that already have held pre-IND meetings and Type C meetings can be requested for nonprescription drug labeling questions.
By: Derrick Gingery
The new prescription drug user fee agreement includes a small decrease in the starting revenue target and fewer adjustments, which could mean lower application and other fees.
By: Derrick Gingery
Reorganization will move HR, IT and other shared services into one office will take effect later this year, but changes to the ‘generalist’ inspection approach were not included.
By: Sue Sutter, Derrick Gingery
Pink Sheet editors review and analyze the major points industry and stakeholders should take from the PDUFA VIII and GDUFA IV commitment letters.
The incentives encouraging US-based clinical trials may be more attractive for new drug sponsors than generic drug domestic manufacturing inducements, but Congress could sweeten them.
By: Derrick Gingery
The GDUFA IV commitment letter will rename formal meetings and streamline its structure, as well as create a new goal date extension for complex regulatory issues.
By: Derrick Gingery, Maaisha Osman
Pink Sheet editors and reporter discuss new FDA commissioner nominee Heidi Overton, her prospects for confirmation, and what her pick means for the agency.
